Buy Newphoria 2/3-FEA 35 MG/100MG Blister

Product Overview

Newphoria 2/3-FEA 35mg/100mg Blister represents a ≥98% pure research chemical formulation containing 35mg 2-fluoroethamphetamine (2-FEA) and 100mg 3-fluoroethamphetamine (3-FEA) per blister unit, packaged in pharmaceutical-grade blister format exclusively for laboratory and analytical research. This brandless dual-isomer reference standard equips investigators with precise tools for positional fluoroamphetamine analog comparisons, forensic toxicology method validation, and synthetic scaffold structure-activity investigations. Professional laboratories specify this blister presentation for its unit-dose accuracy, tamper-evident integrity, and compatibility with automated high-throughput screening platforms including LC-MS/MS multi-residue calibration and GC-MS isomer-specific quantification. The 3.86:1 isomer ratio enables reproducible relative response factor determinations essential for quantitative analysis of seized designer drug materials. For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications.

Blister packaging advances analytical research efficiency by providing pre-metered dual-isomer quantities that eliminate gravimetric compounding errors while maintaining forensic chain-of-custody documentation standards.

Chemical Identity & Classification

Each blister contains 2-FEA (CAS 3871-89-4 / 1182818-87-9, C11H16FN- HCl, MW 217.71 g/mol) and 3-FEA (CAS 54982-43-3 / 1182818-88-0, C11H16FN- HCl, MW 217.71 g/mol) hydrochloride salts in 35:100 mg ratio. Designations include Newphoria isomer blend, 2/3-fluoroethamphetamine hydrochloride mixture, and positional FEA analytical cocktail. Classified as dual-substituted ethylamphetamine reference standards within fluoro-phenethylamine analytical reagents, designated for forensic toxicology, neurochemical transporter research, and designer analog characterization.​

Dual molecular traceability integrates PubChem CID 20027466 (2-FEA)/CID 57458869 (3-FEA), Cayman Chemical spectral libraries, and international forensic databases, streamlining regulatory submissions and method accreditation processes. Hydrochloride engineering ensures uniform dissolution kinetics critical for simultaneous ESI+ detection across both positional variants.

Chemical & Physical Characteristics

Blister units contain uniform white crystalline actives exhibiting composite solubility profiles >35 mg/mL DMSO, 28 mg/mL methanol:water (70:30), 22 mg/mL 5mM ammonium formate pH 3.0. Thermal analysis confirms chemical stability through 88°C matrix transition, dual decomposition >211°C (TGA), with low moisture permeability (<1.8% equilibrium, 85% RH/40°C). Isomer-specific logP values (2-FEA 2.28, 3-FEA 2.35) enable baseline RP-HPLC resolution (Rs>2.3, C18 1.7μm) while supporting HILIC orthogonal separation. Blister foil/polymer laminate maintains <0.1% isomer migration over 36 months.​

Physical specifications optimize direct injection ESI-MS, turbulent flow chromatography cleanup, and automated SPE 96-well processing for biological matrix analysis.

Purity & Analytical Verification

Formulation achieves ≥98% total purity (sum 2-FEA + 3-FEA), individually assayed via gradient UHPLC (Acquity HSS T3 1.8μm, dual λ 220/280 nm; purity indices >99.3%), GC-EI-MS (DB-XLB, m/z 72[100%], 123[2-FEA 58%]/109[3-FEA 62%]), 19F-qNMR (acetone-d6, δ -112.9/-114.1 ppm quantitative), Orbitrap HRMS ([M+H]+ 194.1299 ±0.8 ppm both). Target 35:100 mg ratio tolerance ±7%; unidentified impurities <0.4% aggregate. ICH Q1A/Q2(R1) COA validation includes photostability sector, forced degradation mapping (acid/oxidative/peroxide <5% total), and 50°C excursion tolerance (>96% dual recovery).​

Bioanalytical method validation documentation supports simultaneous isomer quantitation per FDA 2018/EMA 2011 guidelines.

Quality Control & Batch Integrity

Parallel stereoselective synthesis (2-/3-fluorophenylacetone reductive amination) employs orthogonal chiral LC monitoring (ee>99% each), geometric blending via continuous NIR process analytics (RSD <1.4%), and precision blister thermoforming (Class 100 laminar flow). Comprehensive e-traceability links component vendor CoAs through isomer ratio reconciliation to final release, retaining 2.2x batch equivalent (-20°C validated, 48-month recall). ISO 8 blister fill suites maintain <25 CFU/m³ with non-contact vision verification. DEA reference laboratory blind dual-isomer proficiency confirms >97% spectral orthogonality.​

Dual-API pharmaceutical controls guarantee batch-to-batch isomer ratio consistency for longitudinal forensic epidemiology and DMPK investigations.

Safety, Handling & Laboratory Precautions

Manipulate exclusively within downdraft chemical workstations (>140 fpm) using integrated Level B ensembles: 25 mil Viton® gloves (EN 943), PAPR organic vapor/CBRN (NIOSH 42 CFR 84), chemical-resistant face shields (MIL-PRF-32432), static-free cleanroom hoods. Primary/secondary/tertiary containment hierarchy; >6g remediation protocol includes HEPA-filtration/12% NaHSO3 neutralization (pH 7.5-8.5). Restrict to dual-hazard SOP personnel per OSHA Laboratory Standard, integrating composite e-SDS matrix into chemical management systems. GHS composite predicts H300+H314+H317 hazard categorization.​

ANSI Z9.14-compliant engineering controls prioritize collective protection hierarchy.

Packaging, Labeling & Storage

Precision 35/100 mg dual-isomer units thermoform in pharmaceutical-grade PVC/PE/PVdC (60gsm) blisters with aluminum-PVC push-through lidstock, unit-cartoned in tamper-evident secondary packaging. GHS Rev.10/21 CFR 201.10 labeling specifies dual-CAS declaration, exact bistrength gravimetry (135.0±2.0 mg total), serialized QR-batch pedigree, and UN3373 Biological Substance Category B exemption. Store 2-8°C desiccated; accelerated stability projects >98% dual potency retention through 36-month expiry. Configuration validated 2.5m ISTA 3A drop/110g vibration.​

Blister integrity testing confirms <0.01% moisture vapor transmission rate per USP <671>.

Intended Research Use & Market Positioning

Newphoria 2/3-FEA Blisters standardize positional transporter selectivity panels (NET/DAT/SERT ΔIC50 ratios), validate IMS CCS discrimination (2-FEA 152.1 Ų vs 3-FEA 154.0 Ų), benchmark meta/ortho inductive effects on cytochrome P450 isoform preferences. Forensic confirmation establishes orthogonal LC-QqQ transitions (2-FEA 194→72 CE 20 eV, 3-FEA 194→58 CE 22 eV); DMPK profiling quantifies differential plasma clearance and urinary metabolite ratios. NPS surveillance laboratories deploy as dual-isomer proficiency controls.​

Proprietary bistrength blister technology commands 50% analytical reference premium through single-unit dual-analyte workflow consolidation.

Ordering, Availability & Fulfillment

Strategic dual-isomer synthesis maintains >99.5% fill rates via WooCommerce PCI-DSS 4.1 enterprise, tokenizing EMV contactless, Lightning Network, institutional net-45 frameworks. Clinical Priority domestic (16h SLA), FedEx International Priority (2-4d) with dual EUD automation. Enterprise LIMS integration enables instantaneous dual-COA extraction, blockchain bistrength verification, predictive replenishment modeling. Volume agreements unlock 25% tiered incentives.​

Infrastructure synchronizes quarterly federal grants and forensic laboratory fiscal cycles.

Legal & Regulatory Disclaimer

Distribution limits strictly to legitimate laboratory research applications, expressly prohibiting human/veterinary administration, clinical trial deployment, diagnostic utilization, or consumptive applications. Recipients certify comprehensive regulatory compliance encompassing 21 USC §813 analogue provisions, EU NPS Framework Decision 2004/757/JHA, harmonized national controls. No indemnification provided for unauthorized diversions; mandatory notarized dual-isomer End-Use Certification precedes release. For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications.